Novo Nordisk's Ziltivekimab Trial Failure: A Critical Moment for Investors
Novo Nordisk (NVO) shares dropped 9-10% after ziltivekimab missed key trial goals, raising concerns about its pipeline and market valuation.
Replimune's FDA Panel Victory: What Investors Need to Know About RP1 and Its Market Impact
Replimune's shares surged 127-133% following FDA panel support for RP1. Explore the implications for investors and market dynamics.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Dragonfly Energy's Strategic Acquisition: Implications for the Lithium Market
Dragonfly Energy's acquisition of Dakota Lithium assets signals a significant shift in the lithium market landscape.
Capricor Therapeutics Faces a Setback: Analyzing the Impact of FDA's Negative Vote
Capricor Therapeutics shares hit a 52-week low after the FDA advisory committee's negative vote on Deramiocel.
Replimune's Dramatic Surge: What the FDA Panel Vote Means for Investors
Replimune's shares skyrocketed following a key FDA advisory panel vote, signaling potential shifts in biotech investment…
Karyopharm's Price Target Cut: Analyzing the Fallout from Phase 3 Miss
Karyopharm's stock faces a significant downgrade following disappointing trial results, impacting market perception and …
IonQ's Strategic Acquisition of SkyWater: A Game Changer for US Tech
IonQ's acquisition of SkyWater Technology positions it as a leader in quantum computing and semiconductor manufacturing.
Replimune's Successful FDA Advisory Outcome: What It Means for Traders
Replimune (NASDAQ: REPL) sees a record trading day following a positive FDA advisory vote on its melanoma drug RP1.
Intercontinental Exchange (ICE) Acquires MarketAxess (MKTX) in $6B Deal: Implications for US Markets
Intercontinental Exchange's $6B acquisition of MarketAxess signals a seismic shift in the US fixed-income trading landsc…
Pfizer (PFE) Expands LITFULO's Potential with Positive Phase 3 Vitiligo Results
Pfizer's LITFULO shows promise in treating vitiligo, presenting a strategic growth opportunity for investors.
Outlook Therapeutics (OTLK) Faces Market Skepticism Post-FDA Approval of LYTENAVA
Outlook Therapeutics faces skepticism despite FDA approval for LYTENAVA, with shares plummeting 36.3%.